4//SEC Filing
Valeant Pharmaceuticals International, Inc. 4
Accession 0001418812-16-000154
$BHCCIK 0000885590operating
Filed
Jun 20, 8:00 PM ET
Accepted
Jun 21, 9:22 PM ET
Size
22.9 KB
Accession
0001418812-16-000154
Insider Transaction Report
Form 4
VA Partners I, LLC
DirectorOther
Transactions
- Award
Common Stock, no par value
2016-06-17+16,726→ 17,874 total
Holdings
- 1,059,793(indirect: See footnotes)
Common Stock, no par value
- 13,934,468(indirect: See footnotes)
Common Stock, no par value
ValueAct Capital Master Fund, L.P.
DirectorOther
Transactions
- Award
Common Stock, no par value
2016-06-17+16,726→ 17,874 total
Holdings
- 13,934,468(indirect: See footnotes)
Common Stock, no par value
- 1,059,793(indirect: See footnotes)
Common Stock, no par value
ValueAct Co-Invest Master Fund, L.P.
DirectorOther
Transactions
- Award
Common Stock, no par value
2016-06-17+16,726→ 17,874 total
Holdings
- 13,934,468(indirect: See footnotes)
Common Stock, no par value
- 1,059,793(indirect: See footnotes)
Common Stock, no par value
ValueAct Capital Management, LLC
DirectorOther
Transactions
- Award
Common Stock, no par value
2016-06-17+16,726→ 17,874 total
Holdings
- 13,934,468(indirect: See footnotes)
Common Stock, no par value
- 1,059,793(indirect: See footnotes)
Common Stock, no par value
Hale David Robert
DirectorOther
Transactions
- Award
Common Stock, no par value
2016-06-17+16,726→ 17,874 total
Holdings
- 13,934,468(indirect: See footnotes)
Common Stock, no par value
- 1,059,793(indirect: See footnotes)
Common Stock, no par value
ValueAct Capital Management, L.P.
DirectorOther
Transactions
- Award
Common Stock, no par value
2016-06-17+16,726→ 17,874 total
Holdings
- 13,934,468(indirect: See footnotes)
Common Stock, no par value
- 1,059,793(indirect: See footnotes)
Common Stock, no par value
ValueAct Holdings, L.P.
DirectorOther
Transactions
- Award
Common Stock, no par value
2016-06-17+16,726→ 17,874 total
Holdings
- 13,934,468(indirect: See footnotes)
Common Stock, no par value
- 1,059,793(indirect: See footnotes)
Common Stock, no par value
ValueAct Holdings GP, LLC
DirectorOther
Transactions
- Award
Common Stock, no par value
2016-06-17+16,726→ 17,874 total
Holdings
- 13,934,468(indirect: See footnotes)
Common Stock, no par value
- 1,059,793(indirect: See footnotes)
Common Stock, no par value
Footnotes (6)
- [F1]Represents Restricted Share Units ("RSUs") representing a contingent right to receive one share of common stock, no par value, of Valeant Pharmaceuticals International, Inc.
- [F2]Regular annual RSUs equal to $375,000 granted to non-employee directors in office on the third trading day following the Annual Meeting of Shareholders. Pricing is based on the closing price of registrant common stock on the date prior to the grant.
- [F3]This RSU award and all board compensation accrue to the benefit of the investors in ValueAct Capital Master Fund, L.P., and not to any individual. Under an agreement with ValueAct Capital, D. Robert Hale is deemed to hold the restricted share units for the benefit of the limited partners of ValueAct Capital Master Fund, L.P. and indirectly for (i) VA Partners I, LLC as General Partner of ValueAct Capital Master Fund, L.P., (ii) ValueAct Capital Management, L.P. as the manager of ValueAct Capital Master Fund, L.P., (iii) ValueAct Capital Management, LLC as General Partner of ValueAct Capital Management, L.P., (iv) ValueAct Holdings, L.P. as the sole owner of the limited partnership interests of ValueAct Capital Management, L.P. and the membership interests of ValueAct Capital Management, LLC and as the majority owner of the membership interests of VA Partners I, LLC and (v) ValueAct Holdings GP, LLC as General Partner of ValueAct Holdings, L.P.
- [F4]Each reporting person listed herein disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein, and this report shall not be deemed an admission that such person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
- [F5]The securities reported herein are directly beneficially owned by ValueAct Capital Master Fund, L.P. and may be deemed to be indirectly beneficially owned by (i) VA Partners I, LLC as General Partner of ValueAct Capital Master Fund, L.P. , (ii) ValueAct Capital Management, L.P. as the manager of ValueAct Capital Master Fund, L.P. , (iii) ValueAct Capital Management, LLC as General Partner of ValueAct Capital Management, L.P., (iv) ValueAct Holdings, L.P. as the sole owner of the limited partnership interests of ValueAct Capital Management, L.P. and the membership interests of ValueAct Capital Management, LLC and as the majority owner of the membership interests of VA Partners I, LLC and (v) ValueAct Holdings GP, LLC as General Partner of ValueAct Holdings, L.P.
- [F6]The securities reported herein are directly beneficially owned by ValueAct Co-Invest Master Fund, L.P. and may be deemed to be indirectly beneficially owned by (i) VA Partners I, LLC as General Partner of ValueAct Co-Invest Master Fund, L.P. , (ii) ValueAct Capital Management, L.P. as the manager of ValueAct Co-Invest Master Fund, L.P. , (iii) ValueAct Capital Management, LLC as General Partner of ValueAct Capital Management, L.P., (iv) ValueAct Holdings, L.P. as the sole owner of the limited partnership interests of ValueAct Capital Management, L.P. and the membership interests of ValueAct Capital Management, LLC and as the majority owner of the membership interests of VA Partners I, LLC and (v) ValueAct Holdings GP, LLC as General Partner of ValueAct Holdings, L.P.
Documents
Issuer
Valeant Pharmaceuticals International, Inc.
CIK 0000885590
Entity typeoperating
IncorporatedNJ
Related Parties
1- filerCIK 0000885590
Filing Metadata
- Form type
- 4
- Filed
- Jun 20, 8:00 PM ET
- Accepted
- Jun 21, 9:22 PM ET
- Size
- 22.9 KB